CD4 and atherosclerosis: Our results indicate the most important cytokines identifying obstructive CAD are IL-1β, which was indeed chosen as the target of the first anti-inflammatory trial to treat atherosclerosis [8] and IL-12, that drives the CD4 + Th1 response, which is pro-atherogenic [41].